funding neuro
- Company typePrivate
- Founded2011
- HeadquartersGlasgow, United Kingdom
- Headcount—
- GTM typeB2B and B2C
- OfferingServices
funding neuro firmographics
Firmographics- Name
- funding neuro
- Legal name
- Funding Neuro
- Website
- https://fundingneuro.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Ownership category
- akta.pro rank
funding neuro industry classification
Industry- Product category
- Charitable Neurological Research Funding
- NAICS
- Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Grantmaking and Giving Services (81321)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
- akta.pro secondary industries
- Neuro-oncology (HLAKAIAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where funding neuro is headquartered
LocationHeadquarters
- HQ city
- Glasgow
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
funding neuro business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Operations, Others
Revenue model
- Individual Donations: Direct donations from individuals through the website, by post (cheque), electronic bank transfer, or cash collections. Gift Aid scheme allows UK taxpayers to increase donations by 25% at no extra cost to the donor.
- Community Fundraising: Fundraising events organized by supporters including sponsored bike rides, mountain climbs, bake sales, school fetes, birthday parties, collections, and personal challenges. Funds collected through JustGiving and Virgin Money Giving platforms.
- Corporate Partnerships: Partnerships with businesses that provide financial support, staff fundraising, event sponsorship, and donations of time, skills or products. Examples include The New Homes Group raising over £125,000.
- Legacy Gifts: Bequests left to Funding Neuro in supporters' wills. For many large charities, every £1 of every £3 raised comes from legacy gifts.
- Event Revenue: Ticket sales for organized events including Fundraising Sports Lunch (£90 per person, tables of ten at £850), Ladies Brunch (£40 per person), 15th Anniversary Dinner (£100 per person), and Rushfest Scotland tickets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time | Fundraising Sports Lunch tickets |
| Other | One time | Ladies Brunch tickets |
| Other | One time | 15th Anniversary Dinner tickets |
| Other | One time | Rushfest Scotland tickets |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
funding neuro product offering
Product offeringCore offering
Funding Neuro is a Scottish registered charity that raises funds through donations, events, and corporate partnerships to finance clinical trials and applied research for serious neurological conditions including DIPG, glioblastoma, Parkinson's disease, and Motor Neurone Disease. The charity supports innovative drug delivery technologies such as Convection Enhanced Delivery, focused ultrasound-based Sonodynamic Therapy, and CAR-T cell immunotherapy that aim to breach the blood-brain barrier and deliver new treatments to patients.
Product overview
Funding Neuro is a registered Scottish charity (SC042061) focused on funding applied research and clinical trials for neurological conditions and brain cancers. Rather than operating a software product, the organization supports and funds medical research programs including Convection Enhanced Delivery (CED) for brain tumor treatment, CAR-T Cell Therapy trials for DIPG, Sonodynamic Therapy, GDNF therapy for Parkinson's Disease, and Ambroxol Phase 3 clinical trials. The organization facilitates fundraising appeals, community fundraising events, corporate partnerships, and legacy giving programs to generate funds for these research initiatives. Funding Neuro collaborates with universities, hospitals (including Great Ormond Street Hospital and University of Bristol), and other charities to advance neurological treatment research.
Differentiator
Problem solved
Functional benefit
Products and services
- Rushfest Scotland A multi-day ticketed music and fundraising festival held in Glasgow on 15th, 16th, and 17th May 2026. Tickets are sold through tickets-scotland.com, with all profits going to Funding Neuro and Beatson Cancer.
- Ladies Brunch Ticketed fundraising brunch event held in Glasgow with tickets at £40 per person. Includes arrival drink, 3-course lunch, country-themed entertainment with host Edward Reid, games, and prizes.
- 15th Anniversary Dinner A ticketed anniversary dinner dance held at Glasgow Central Hotel, Halloween themed, with tickets at £100 per person or tables of 10 for £1,000. Includes compere Des Clarke and music from Wonderland.
- Fundraising Sports Lunch A ticketed sports-themed fundraising lunch with individual tickets at £90 per person, tables of 10 at £850, and tables of 12 at £1,020. Includes arrival drink, 3-course lunch, sports banter with hosts Tam Cowan and Alan Rough, fundraising auction, entertainment, and games.
- Corporate Partnerships Programme A programme for businesses to provide financial support, staff fundraising, event sponsorship, and donations of time, skills, or products to Funding Neuro. Example partner The New Homes Group raised over £125,000 in their first year.
- Leave a Legacy / Bequest Programme A programme enabling supporters to leave bequests to Funding Neuro in their wills. Legacy giving is described as a critical revenue stream where, for many large charities, every £1 of every £3 raised comes from legacy gifts.
Quantifiable outcome
- 18 children with DIPG treated under compassionate programme with MHRA approval
- +4 more outcomes
Companies that use funding neuro
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
funding neuro technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
funding neuro partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- The New Homes GroupcoreCorporate charity partner that raised over £125,000 in their first year through staff fundraising, selling Daisy pin badges, bake offs, dress down days, and their own Daisy Card. Continued supporting through regular corporate donations. See similarities in Funding Neuro's vision and are helping achieve it.
- Great Ormond Street Hospital (GOSH)coreLocation of CAR-T cell therapy trial for DIPG patients (phase 1 study of GD2 CAR-T-cells for H3K27M+DMG). NHS eligible patients age 2-16 from throughout UK can participate. Funding Neuro contributed £300,000 of the £1.2m trial cost.
- Professor Steven Gill (University of Bristol)coreProfessor of Neurosurgery leading convection enhanced delivery (CED) research for DIPG treatment. Developed the four-catheter drug delivery system that bypasses the blood-brain barrier. Funding Neuro has supported his work over a number of years, including treating 18 children under compassionate use with MHRA approval.
- SonALAsensecoreAmerican company providing ALA (5-aminolevulinic acid) chemical used in Sonodynamic Therapy. The combination of Insightec Ultrasound device with ALA has been proven in US safety trials to safely produce Sonodynamic therapy to reduce tumour size without invasive surgery.
- InsighteccoreManufacturer of focused ultrasound device being raised funds to purchase (£400k target). The device combined with SonALAsense's ALA chemical enables non-invasive Sonodynamic therapy treatment for DIPG and glioblastoma.
- Anima Mundi Art GalleryminorArt gallery in St Ives, Cornwall that donated nearly £3,000 to Funding Neuro from their Winter Print Edition. Donation made in memory of Daisy Brooks and Ethan Cass who lost their lives to DIPG.
- CureGBMcoreCharity working with Funding Neuro to raise funds for Sonodynamic Therapy to treat glioblastoma. Partnering with Professor Philippe Schucht in Switzerland for innovative GBM trial using SDT. UK patients will be eligible for treatment.
- Dr Kismet Hossain-IbrahimcoreResearcher leading the Dundee Ultrasound Appeal to purchase Insightec Ultrasound device (£400k target) for Sonodynamic therapy trials treating both DIPG and Glioblastoma patients.
- Professor Philippe SchuchtcoreRenowned neuro-oncology Professor of Neurosurgery in Switzerland working with CureGBM and Funding Neuro to deliver innovative glioblastoma trial using Sonodynamic Therapy.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
funding neuro competitors and assessment
Company assessmentDirect peers
- Van Andel Institute: US-based biomedical research institute focused on Parkinson's and other neurodegenerative diseases. Direct peer — joint funder of the Ambroxol Phase 3 trial, sharing translational neurological research priorities.
- MND Association: UK Motor Neurone Disease research and support charity. Direct peer — shares MND research funding mandate and UK charity donor base with Funding Neuro's MND pre-clinical programme.
- The Brain Tumour Charity: UK charity funding brain tumour research and support. Direct peer — overlaps directly on DIPG and Glioblastoma, the same conditions that anchor Funding Neuro's CED and Sonodynamic Therapy programmes.
- Cure Parkinson's: UK charity funding research to slow, stop and reverse Parkinson's disease. Direct peer — joint funder with Funding Neuro of the £5.4m Ambroxol Phase 3 trial and shares the translational research mandate.
- Brain Research UK: UK charity funding neurological research across multiple conditions. Direct peer — operates the same model of funding academic and clinical research into brain and neurological disorders in the UK.
- My Name'5 Doddie Foundation: Scottish MND research charity. Direct peer — co-funded the £225k MND pre-clinical stage with Funding Neuro and Alan Davidson Foundation, sharing both disease focus and small-team UK charity model.
- Parkinson's UK: UK Parkinson's research and support charity. Direct peer — co-funds the Ambroxol Phase 3 trial alongside Funding Neuro, Cure Parkinson's, Van Andel Institute and John Black Foundation.
- Michael J. Fox Foundation for Parkinson's Research: US-based Parkinson's research funder. Direct peer — same disease-research-funding model applied to Parkinson's; relevant comparator for translational research grant-making scale and donor mobilisation.
Broad incumbents
- Wellcome Trust: Large UK charitable foundation funding biomedical and neurological research. Broad incumbent — relevant comparator on research-funding scale, governance and translational mandate, even though its scope is much wider.
- Cancer Research UK: UK's largest cancer research charity. Broad incumbent — funds brain tumour research (including DIPG/GBM) at much greater scale; sets the broader funding environment Funding Neuro operates within.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
funding neuro social profiles
Digital presencefunding neuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
funding neuro leadership team
Management profileNumber of profiles
Profiles7 records
funding neuro funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
funding neuro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about funding neuro
What does funding neuro do?
Funding Neuro is a Scottish registered charity that raises funds through donations, events, and corporate partnerships to finance clinical trials and applied research for serious neurological conditions including DIPG, glioblastoma, Parkinson's disease, and Motor Neurone Disease. The charity supports innovative drug delivery technologies such as Convection Enhanced Delivery, focused ultrasound-based Sonodynamic Therapy, and CAR-T cell immunotherapy that aim to breach the blood-brain barrier and deliver new treatments to patients.
Is funding neuro a public or private company?
funding neuro is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was funding neuro founded?
funding neuro was founded in 2011.
Where is funding neuro based?
funding neuro is headquartered in Glasgow, United Kingdom, in the Europe region.
How does funding neuro make money?
Five revenue lines are on record. Individual Donations are the primary driver. The others are community Fundraising, corporate Partnerships, legacy Gifts and event Revenue.
Who are funding neuro's main competitors?
Direct peers on record are Van Andel Institute, MND Association, The Brain Tumour Charity, Cure Parkinson's, Brain Research UK, My Name'5 Doddie Foundation, Parkinson's UK and Michael J. Fox Foundation for Parkinson's Research. Broad incumbents are Wellcome Trust and Cancer Research UK.
Does funding neuro have an API?
No public API is recorded for funding neuro.
What industry is funding neuro in?
funding neuro's product category is Charitable Neurological Research Funding. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAKAIAL, Neuro-oncology. Its NAICS code is 813212 and its SIC code is 8731.